HC Wainwright Reiterates Buy Rating for Femasys (NASDAQ:FEMY)

HC Wainwright reaffirmed their buy rating on shares of Femasys (NASDAQ:FEMY) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock. HC Wainwright also issued estimates for Femasys’ Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.14) EPS and FY2029 earnings at $0.01 EPS.

Separately, Chardan Capital decreased their price target on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Trading Up 4.5 %

NASDAQ:FEMY opened at $1.38 on Tuesday. The stock has a fifty day moving average price of $1.14 and a two-hundred day moving average price of $1.12. The stock has a market capitalization of $31.60 million, a price-to-earnings ratio of -1.70 and a beta of -2.81. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. Femasys has a 1 year low of $0.86 and a 1 year high of $2.40.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. As a group, sell-side analysts anticipate that Femasys will post -0.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in shares of Femasys during the 4th quarter valued at approximately $25,000. Aljian Capital Management LLC bought a new position in shares of Femasys during the 3rd quarter valued at about $27,000. XTX Topco Ltd raised its position in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after purchasing an additional 17,473 shares during the period. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.